Experimental Human Pneumococcal Challenge With SPN3
NCT05535868 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 117
Last updated 2022-09-21
Summary
The 'Experimental Human Pneumococcal challenge' (EHPC) model is a way of putting drops of bacteria into the nose. Investigators have studied this model of putting bacteria in the nose safely in over 1500 volunteers over the past decade with no serious side effects and now want to test the model using a different strain of the bacteria that is commonly found in the community, SPN3.
The aim of this study is to determine how much pneumococcus is needed to achieve nasal colonisation and how long the bacteria live in the nose for before natural immune responses eradicate them. By doing this, Investigators will then be able to test how well future vaccines prevent colonisation with pneumococcus. Investigators want to learn more about how the immune system responds to nasal colonisation with pneumococcus, again to help with development of new vaccines.
Conditions
- Streptococcus Pneumonia
Interventions
- OTHER
-
SPN3 innoculation
Healthy adult participants aged 18-50 (inclusive) will be inoculated with pure culture of well-characterised, fully sequenced amoxicillin-sensitive SPN3. They will be observed for safety and development of pneumococcal colonisation
Sponsors & Collaborators
- collaborator INDUSTRY
-
Liverpool School of Tropical Medicine
lead OTHER
Principal Investigators
-
Andrea Collins, MBChB, PhD · Senior Clinical Lecturer
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-08-01
- Primary Completion
- 2023-08-01
- Completion
- 2023-08-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Study Evaluating Streptococcus Pneumoniae Nasopharyngeal Carriage Rate in Children Receiving Prevnar®
NCT00488371 ·Status: COMPLETED
-
A Study of V118E in Healthy Participants (V118E-003)
NCT07168915 ·Status: RECRUITING ·Phase: PHASE1
-
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
NCT03828617 ·Status: COMPLETED ·Phase: PHASE3
-
Nasopharyngeal Carriage Study in Healthy Kenyan Toddlers
NCT02146365 ·Status: COMPLETED
-
Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers
NCT01444001 ·Status: COMPLETED ·Phase: PHASE1
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants
NCT04382326 ·Status: COMPLETED ·Phase: PHASE3
-
Phase I to Test a New Pneumococcal Vaccine
NCT03303976 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Streptococcus Pneumoniae in Nose and Throats of Infants With Acute Otitis Media
NCT00195611 ·Status: COMPLETED
-
A Study to Learn About How a New Pneumococcal Vaccine Works in Adults
NCT07086677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization
NCT00508742 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age
NCT05489328 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.
NCT05875727 ·Status: COMPLETED ·Phase: PHASE3
-
Dose-Finding Study of S.Pneumoniae Whole Cell Vaccine Adsorbed to Alum (PATH-wSP) in Healthy Kenyan Adults and Toddlers
NCT02097472 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07035054 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Efficacy Study of Prophylactic S. Pneumoniae Vaccine Following Challenge With S. Pneumoniae
NCT02116998 ·Status: COMPLETED ·Phase: PHASE2
-
A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine
NCT03803202 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults
NCT00744263 ·Status: COMPLETED ·Phase: PHASE4
-
PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate Vaccine
NCT07025876 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
NCT04530838 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant
NCT07023081 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)
NCT04974294 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Assess the Safety, Tolerability and Immunogenicity of ASP3772, a Pneumococcal Vaccine, in Toddlers 12 to 15 Months of Age in Comparison to an Active Comparator
NCT04525599 ·Status: COMPLETED ·Phase: PHASE1
-
An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi
NCT04078997 ·Status: COMPLETED
-
A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults
NCT05831124 ·Status: COMPLETED ·Phase: PHASE1
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Japanese Infants
NCT00574795 ·Status: COMPLETED ·Phase: PHASE3